REGENERON UK LIMITED
Get an alert when REGENERON UK LIMITED files next
Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.
Next accounts due
2026-09-30 (in 4mo)
Last filed for 2024-12-31
Confirmation statement due
2027-02-28 (in 9mo)
Last made up 2026-02-14
Watchouts
None on the register
Cash
£30M
+19,159.1% vs 2023
Net assets
£19M
+57.1% vs 2023
Employees
268
+24.7% vs 2023
Profit before tax
£10M
+45.4% vs 2023
Net assets
2-year trend · vs Industrials median
Accounts
2-year trend · latest reflected 2024-12-31
| Metric | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Turnover | £72,987,555 | £84,386,150 | |
| Operating profit | £6,541,732 | £10,403,545 | |
| Profit before tax | £6,649,371 | £9,667,549 | |
| Net profit | £5,712,367 | £7,070,502 | |
| Cash | £156,306 | £30,103,155 | |
| Total assets less current liabilities | £12,385,094 | £19,455,596 | |
| Net assets | £12,385,094 | £19,455,596 | |
| Equity | £12,385,094 | £19,455,596 | |
| Average employees | 215 | 268 | |
| Wages | £35,991,519 | £40,787,074 |
Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers
Ratios
Computed from the line items above — sparklines read oldest → newest
| Ratio | Trend | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating margin | 9.0% | 12.3% | |
| Net margin | 7.8% | 8.4% | |
| Return on capital employed | 52.8% | 53.5% | |
| Gearing (liabilities / total assets) | 76.4% | 76.1% | |
| Current ratio | 1.11x | 1.21x | |
| Interest cover | 28.86x | 7.95x |
Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.
Audit & accounting basis
- Accounting basis
- FRS 102
- Reporting scope
- Standalone (parent only)
- Auditor
- PricewaterhouseCoopers LLP
- Audit opinion
- Unqualified (clean)
- Going concern
- Affirmed
“These financial statements have been prepared on a going concern basis, which the Directors believe to be appropriate. The Company is funded through providing development services, including clinical development services, primarily in connection with the development of RIRE products and product candidates. Further, Regeneron, its ultimate parent, has provided a letter of support to ensure that the Company can meet its obligations for a period of at least twelve months from the issuance of these financial statements. Additionally, the Company does not currently have the intention nor the need to liquidate or cease its operations in the foreseeable future.”
Significant events
- “From February 2025, the Company started its commercial distribution activities in the UK, including recording product sales to third parties.”
- “On 1 January 2024, the Company has changed its presentation and functional currency from U.S. dollars to Great British Pound (GBP). As a result, comparative figures for the prior period have been restated from U.S. dollars to Great British Pound (GBP).”
- “Effective 1 January 2024, the Company entered into a credit agreement for a revolving credit facility with RIRE. The facility is GBP denominated, has no fixed repayment terms, provides for borrowings in an aggregate amount not to exceed £40,000,000 at any time outstanding and is repayable by 1 January 2027.”
Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers
People
3 active · 7 resigned
| Name | Role | Appointed | Born | Nationality |
|---|---|---|---|---|
| ACCOMPLISH SECRETARIES LIMITED | Corporate Secretary | 2017-03-31 | — | — |
| BERKOVIC, Zoran | Director | 2018-05-16 | Aug 1977 | American |
| VOLPE, Mark | Director | 2016-10-19 | Jul 1972 | American |
Show 7 resigned officers
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| SKADDEN, ARPS, SLATE, MEAGHER & FLOM (CORPORATE SERVICES) LIMITED | Corporate Secretary | 2007-02-15 | 2017-03-31 |
| SWIFT INCORPORATIONS LIMITED | Corporate Nominee Secretary | 2007-02-15 | 2007-02-15 |
| FENIMORE, Christopher Robert | Director | 2014-07-18 | 2024-02-06 |
| GOLDBERG, Murray. A | Director | 2007-02-15 | 2014-07-18 |
| LANDRY, Jeffrey | Director | 2016-10-19 | 2018-05-16 |
| MCCORKLE, Douglas Steven | Director | 2014-07-18 | 2016-10-12 |
| SCHLEIFER, Leonard. S | Director | 2007-02-15 | 2014-07-18 |
Ownership
Persons with significant control
| Name | Kind | Nature of control | Notified | Status |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | Corporate entity | Shares 75–100%, Voting 75–100%, Appoints directors | 2016-04-06 | Active |
Filing timeline
Last 20 of 64 total filings
| Date | Type | Category | Description | |
|---|---|---|---|---|
| 2026-02-20 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2025-09-12 | AA | accounts | Accounts with accounts type full | |
| 2025-02-17 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2024-10-14 | AA | accounts | Accounts with accounts type full | |
| 2024-02-26 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2024-02-09 | TM01 | officers | Termination director company with name termination date | |
| 2023-12-13 | CH01 | officers | Change person director company with change date | |
| 2023-08-22 | AA | accounts | Accounts with accounts type full | |
| 2023-02-14 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2022-06-17 | AA | accounts | Accounts with accounts type full | |
| 2022-02-21 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2021-06-21 | AA | accounts | Accounts with accounts type full | |
| 2021-02-17 | CS01 | confirmation-statement | Confirmation statement with no updates | |
| 2020-06-22 | AA | accounts | Accounts with accounts type small | |
| 2020-02-18 | CS01 | confirmation-statement | Confirmation statement with updates | |
| 2020-02-18 | CH01 | officers | Change person director company with change date | |
| 2020-02-18 | CH01 | officers | Change person director company with change date | |
| 2020-02-18 | CH01 | officers | Change person director company with change date | |
| 2019-10-15 | AD01 | address | Change registered office address company with date old address new address | |
| 2019-08-28 | AA | accounts | Accounts with accounts type small |
Public-record activity
Raw counts from Companies House — last 12–24 months
- Filings
- 2
- Capital events
- 0
- Officers appointed
- 0
- Officers resigned
- 0
last 12 months
last 24 months
last 12 months
last 12 months
Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.
Year-on-year
FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31
-
Turnover
+15.6%
£72,987,555 £84,386,150
-
Cash
+19,159.1%
£156,306 £30,103,155
-
Net assets
+57.1%
£12,385,094 £19,455,596
-
Employees
+24.7%
215 268
-
Operating profit
+59%
£6,541,732 £10,403,545
-
Profit before tax
+45.4%
£6,649,371 £9,667,549
-
Wages
+13.3%
£35,991,519 £40,787,074
Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers